Mon. May 25th, 2026
Spread the love

The Court of Appeal in Abuja  said on Monday that it would no longer hear applications for stay of proceedings in the trials of the Senate President, Dr. Bukola Saraki, former National Security Adviser, Col. Sambo Dasuki (retd), and the National Publicity Secretary of the Peoples Democratic Party, Chief Olisa Metuh.

 Justice Abdul Aboki who presided over the three-man panel of the appeal court when Metuh’s appeal was mentioned on Monday gave a clear warning against the filing of notice of stay of proceedings.

“We have decided that we will not hear motion for stay of proceedings. You should go back to the court to argue your application before the court and pursue your appeal before us,” Justice Aboki said.

 He did not say whether the court’s position was only limited to only criminal cases or it would also affect civil appeals.

In response, Metuh’s lawyer, Mr. Onyechi Ikpeazu (SAN), said he thought he would be allowed to convince the court on the merit of the motion for stay of proceedings which he filed on behalf of his client.

Justice Aboki, further affirming the court’s position in a reply, said, “We are not going to allow that, even if you file it we are going to dismiss it straightaway.”

Metuh and his company, Destra Investments Limited, had filed separate notices of appeal against the ruling of Justice Okon Abang of the Federal High Court in Abuja dismissing their application for no-case submission.

The PDP’s spokesperson is being prosecuted along with his company before Justice Abang by the Economic and Financial Crimes Commission on seven counts, including money laundering involving $2m cash transaction.

Other counts bordered on alleged fraud involving N400m which he allegedly received in November 2014 from the office of the NSA then being occupied by Dasuki.

The Court of Appeal on Monday directed the prosecuting counsel, Mr. Tahir Sylvanus,  to file new separate notices of appeal, instead of the only one which he had filed, against the two notices of appeal filed for Metuh and Destra Investments Limited.

Metuh’s appeal was adjourned till May 5 for hearing.

On his part, Saraki filed an appeal before the appeal court to challenge the March 24, 2016, ruling of the Code of Conduct Tribunal in Abuja, where he is being prosecuted on 13 counts of false asset declaration.

Earlier on Monday, Saraki’s  lawyer, Chief Kanu Agabi (SAN), who appeared before the three-man panel of the appeal court, voluntarily withdrew the application for stay of proceedings which he filed accompanying his client’s notice of appeal.

But Dasuki’s lawyer, Mr. Joseph Daudu (SAN),  who also appeared before the same appeal court’s panel on Monday with respect to his client’s appeal, said he would take the decision on whether or not to withdraw his motions for stay of proceedings after receiving EFCC’s respondents brief.

“If I see the respondent brief, I will be able to make the decision,” Daudu said.

Dasuki filed the notices of appeal with respect to two separate appeals challenging the rulings of Justices Baba Yusuf and Peter Affen of the Federal Capital Territory High Court in Maitama dismissing the former NSA’s applications seeking the orders stopping his trial.

Justices Yusuf and Affen had on February 8 and March 4, respectively, dismissed the separate applications by Dasuki asking for orders prohibiting the EFCC from prosecuting him on two sets of charges of diversion of funds meant for procurement of arms.

Justice Adeniyi Ademola of a Federal High Court in Abuja also on April 19 dismissed a similar application which like the two others was anchored on the ex-NSA’s continued detention in the custody of the Department of State Service since December 29, 2015.

The appeal court said on Monday that dates for hearing the appeals by Saraki and Dasuki would be communicated to the parties through their lawyers.

 

By admin

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.